| 杨咪,彭正加,郭炼,等.喉癌病人血清胸苷激酶 1、let-7a、垂体瘤转化基因 1的水平及其联合检测的预后价值[J].安徽医药,2026,30(9):1831-1835. |
| 喉癌病人血清胸苷激酶 1、let-7a、垂体瘤转化基因 1的水平及其联合检测的预后价值 |
| Serum levels of thymidine kinase 1, let-7a, and pituitary tumor transforming gene 1 in patients with laryngeal cancer and their combined prognostic value |
| |
| DOI：10.3969/j.issn.1009-6469.2026.09.025 |
| 中文关键词: 喉肿瘤 胸苷激酶 1 let-7a 垂体瘤转化基因 1 预后 预测价值 |
| 英文关键词: Laryngeal neoplasms Thymidine kinase 1 Let-7a value |
| 基金项目:第十一批创新型省份建设专项资金项目( 2023ZK4295)；湘潭市指导性科技计划项目( SF-ZDJH20241035) |
|
| 摘要点击次数: 261 |
| 全文下载次数: 36 |
| 中文摘要: |
| 目的探究喉癌病人血清胸苷激酶 1(TK1)、微 RNA let-7a、垂体瘤转化基因 1(PTTG1)的水平及其联合检测的预后价值。方法回顾性研究。选取 2021年 1月至 2023年 1月湘潭市中心医院(湖南大学附属医院) 150例喉癌病人作为喉癌组，另选同期 75例喉良性病变(均为声带息肉)病人作为良性组， 75例健康体检者作为健康组。比较三组血清 TK1、let-7a、PTTG1水平，分析喉癌组血清 TK1、let-7a、PTTG1三者之间的相关性。比较喉癌组预后不良与预后良好病人治疗前一般资料、血清 TK1、 let-7a、PTTG1水平，分析预后不良影响因素，并分析血清 TK1、let-7a、PTTG1对预测预后不良的价值，将常规影响因素(年龄、肿瘤长径、分化程度、淋巴结转移、临床分期)联合作为常规预测方案，在常规预测方案基础上联合血清 TK1、let-7a、PTTG1水平作为新预测方案，比较两种预测方案预测预后的预测价值。结果喉癌组血清 TK1［( 3.57±0.94)pmol/L］、 PTTG1［( 126.57± 31.74)ng/L］水平高于良性组［(2.14±0.68)pmol/L、(101.32±20.59)ng/L］、健康组［( 1.21±0.35)pmol/L、(72.36±18.14)ng/L］，let-7a(0.85±0.24)水平低于良性组( 1.18±0.31)、健康组( 1.27±0.26)(P<0.05)良性组血清 TK1、PTTG1水平高于健康组， let-7a水平低于健康组( P<0.05)；喉癌组血清 TK1、PTTG1水平与 let-7a水平呈负相关，，血清 TK1水平与 PTTG1水平呈正相关( P<0.05)；喉癌组预后不良病人年龄、肿瘤长径 >4 cm占比、淋巴结转移占比、临床分期 Ⅲ~Ⅳ期占比、血清 TK1、PTTG1水平高于预后良好病人，分化程度中高分化占比、血清 let-7a水平低于预后良好病人(P<0.05)；年龄、肿瘤长径、分化程度、淋巴结转移、临床分期、血清 TK1、let-7a、PTTG1均为喉癌病人预后不良的影响因素( P<0.05)；血清 TK1、let-7a、PTTG1预测喉癌病人预后不良的曲线下面积( AUC)及其 95%CI分别为 0.74(0.67，0.81)、 0.75(0.67，0.82)、 0.73(0.65，0.80)；常规预测方案预测喉癌病人预后不良的 AUC及其 95%CI为 0.84(0.77，0.90)；新预测方案预测喉癌病人预后不良的 AUC及其 95%CI为 0.93(0.88，0.97)净重新分类指数(NRI)、综合判别改善指数(IDI)均 >0(P<0.05)。结论喉癌病人血清 TK1、PTTG1水平升高，血清 let-7a水平降，低，与预后不 |
| 英文摘要: |
| Objective To investigate the serum levels of thymidine kinase 1 (TK1), microRNA let-7a and pituitary tumor transform. ing gene 1 (PTTG1) in laryngeal cancer patients and their combined prognostic value.Methods This was a retrospective study. A totalof 150 laryngeal cancer patients treated from January 2021 to January 2023 at Xiangtan Central Hospital (Affiliated Hospital of HunanUniversity) were selected as the laryngeal cancer group. Another 75 patients with benign laryngeal lesions (all vocal cord polyps) wereselected as the benign group during the same period. Additionally, 75 healthy individuals who underwent a physical examination wereselected as the healthy group. Serum levels of TK1, let-7a, and PTTG1 were compared among the three groups, and the correlation be. tween serum TK1, let-7a, and PTTG1 levels in the laryngeal cancer group were analyzed. Baseline characteristics and serum TK1, let-7a, and PTTG1 levels before treatment were compared between patients with poor prognosis and those with good prognosis in the laryn.geal cancer group, and factors influencing poor prognosis were analyzed. The value of serum TK1, let-7a, and PTTG1 in predicting poorprognosis was also analyzed. Conventional influencing factors (age, tumor diameter, degree of differentiation, lymph node metastasisand clinical stage) were combined as a conventional prediction scheme, and serum TK1, let-7a, and PTTG1 levels were added to theconventional prediction scheme as a new prediction scheme. The predictive values of the two prediction schemes for prognosis were compared.Results Serum TK1 [(3.57±0.94) pmol/L] and PTTG1[(126.57±31.74) ng/L] in the laryngeal cancer group were higher thanthose in the benign group [(2.14±0.68) pmol/L, (101.32±20.59) ng/L] and the healthy group [(1.21±0.35) pmol/L, (72.36±18.14) ng/L],while let-7a level (0.85±0.24) was lower than that in the benign group (1.18±0.31) and the healthy group (1.27±0.26) (P<0.05). Serum TK1 and PTTG1 levels in the benign group were higher than those in the healthy group, and let-7a level was lower than that in the healthy group (P<0.05). In the laryngeal cancer group, serum TK1 and PTTG1 levels were negatively correlated with let-7a level, and serum TK1 level was positively correlated with PTTG1 level (P<0.05). Among the laryngeal cancer patients, those with poor prognosishad significantly higher age, higher proportions of tumor diameter >4 cm, lymph node metastasis, and clinical stage Ⅲ-Ⅳ, and higher serum TK1 and PTTG1 levels compared to those with good prognosis, while the proportion of moderate-to-high differentiation and se. rum let-7a level were lower (P<0.05). Age, tumor diameter, degree of differentiation, lymph node metastasis, clinical stage, and serum TK1, let-7a, and PTTG1 levels were all influencing factors for poor prognosis in patients with laryngeal cancer (P<0.05). The areas un. der the curve (AUC) of serum TK1, let-7a, and PTTG1 for predicting poor prognosis in patients with laryngeal cancer were 0.74 [95%CI: (0.67, 0.81)], 0.75 [95%CI: (0.67, 0.82)], and 0.73 [95%CI: (0.65, 0.80)], respectively. The AUC of the conventional prediction scheme for predicting poor prognosis was 0.84 [95%CI: (0.77, 0.90)], while the AUC of the new prediction scheme was 0.93 [95%CI: (0.88, 0.97)]. Compared with the conventional prediction scheme, the net reclassification improvement (NRI) and integrated discrimina.tion improvement (IDI) were both >0 (P<0.05).Conclusion Elevated serum TK1 and PTTG1 and decreased serum let-7a level in pa. tients with laryngeal cancer are significantly associated with poor prognosis and have prognostic value. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
